Free Trial

Maravai LifeSciences (MRVI) Stock Forecast & Price Target

$10.95
-0.39 (-3.44%)
(As of 05/21/2024 ET)

Maravai LifeSciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Consensus Price Target

$11.44
4.52% Upside
High Forecast$17.00
Average Forecast$11.44
Low Forecast$7.00
TypeCurrent Forecast
5/23/23 to 5/22/24
1 Month Ago
4/23/23 to 4/22/24
3 Months Ago
2/22/23 to 2/22/24
1 Year Ago
5/23/22 to 5/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.44$11.56$13.22$19.80
Forecasted Upside4.52% Upside49.88% Upside48.44% Upside41.82% Upside
Get Maravai LifeSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.

MRVI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRVI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Maravai LifeSciences Stock vs. The Competition

TypeMaravai LifeSciencesMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.69
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside4.52% Upside713.29% Upside8.27% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/9/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$8.00 ➝ $10.00+12.74%
4/10/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$15.00+76.26%
2/23/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$12.00 ➝ $14.00+72.20%
2/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$11.00 ➝ $10.00+95.69%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$10.00 ➝ $8.00+55.34%
11/9/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$8.00 ➝ $7.00+53.17%
11/9/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$12.00 ➝ $11.00+132.07%
8/8/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$23.00 ➝ $17.00+52.60%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$14.00 ➝ $11.00-0.18%
8/8/2023KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Sector Weight
5/23/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
1/5/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$20.00 ➝ $16.00+14.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:46 AM ET.

MRVI Frequently Asked Questions

What is Maravai LifeSciences's stock forecast and purchase recommendation?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Maravai LifeSciences is $11.44, with a high forecast of $17.00 and a low forecast of $7.00. The consensus rating for Maravai LifeSciences stock is Moderate Buy based on the current 3 hold ratings and 7 buy ratings for MRVI. Learn more on MRVI's analyst rating history.

Do Wall Street analysts like Maravai LifeSciences more than its competitors?

Analysts like Maravai LifeSciences more than other "medical" companies. The consensus rating score for Maravai LifeSciences is 2.70 while the average consensus rating score for "medical" companies is 2.69. Learn more on how MRVI compares to other companies.

Does Maravai LifeSciences's stock price have much upside?

According to analysts, Maravai LifeSciences's stock has a predicted upside of 53.18% based on their 12-month stock forecasts.

What analysts cover Maravai LifeSciences?

Maravai LifeSciences has been rated by research analysts at Craig Hallum, Robert W. Baird, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:MRVI) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners